Senseonics (NYSE:SENS) Sets New 12-Month High - Should You Buy?

Senseonics Holdings, Inc. (NYSE:SENS - Get Free Report) hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $1.20 and last traded at $1.06, with a volume of 18589708 shares traded. The stock had previously closed at $1.13.

Analyst Ratings Changes

SENS has been the subject of several analyst reports. HC Wainwright reissued a "buy" rating and issued a $2.00 price objective on shares of Senseonics in a research note on Friday, November 15th. StockNews.com initiated coverage on shares of Senseonics in a research note on Thursday, December 26th. They issued a "sell" rating for the company.

Senseonics Trading Up 4.8 %

The company has a market capitalization of $648.91 million, a PE ratio of -8.38 and a beta of 0.64. The company's fifty day moving average is $0.56 and its 200-day moving average is $0.44. The company has a debt-to-equity ratio of 59.17, a current ratio of 2.47 and a quick ratio of 2.38.

Senseonics (NYSE:SENS - Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($0.01). The business had revenue of $4.26 million for the quarter, compared to analysts' expectations of $4.02 million. Senseonics had a negative net margin of 362.30% and a negative return on equity of 842.25%. On average, analysts anticipate that Senseonics Holdings, Inc. will post -0.14 EPS for the current fiscal year.

Insider Activity at Senseonics

In other news, CEO Timothy T. Goodnow purchased 315,000 shares of the business's stock in a transaction on Tuesday, December 10th. The shares were acquired at an average cost of $0.31 per share, with a total value of $97,650.00. Following the completion of the acquisition, the chief executive officer now owns 11,310,355 shares of the company's stock, valued at $3,506,210.05. This trade represents a 2.86 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Frederick T. Sullivan purchased 124,933 shares of the business's stock in a transaction on Thursday, December 12th. The stock was purchased at an average cost of $0.38 per share, for a total transaction of $47,474.54. Following the completion of the acquisition, the chief financial officer now directly owns 2,478,844 shares of the company's stock, valued at approximately $941,960.72. The trade was a 5.31 % increase in their position. The disclosure for this purchase can be found here. 3.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Senseonics

A number of large investors have recently made changes to their positions in the stock. Ridgecrest Wealth Partners LLC acquired a new position in Senseonics during the fourth quarter valued at $60,000. Geode Capital Management LLC grew its stake in shares of Senseonics by 3.2% in the 3rd quarter. Geode Capital Management LLC now owns 5,838,396 shares of the company's stock valued at $2,042,000 after buying an additional 179,103 shares during the period. FMR LLC grew its stake in shares of Senseonics by 48,267.2% in the 3rd quarter. FMR LLC now owns 168,318 shares of the company's stock valued at $59,000 after buying an additional 167,970 shares during the period. GSA Capital Partners LLP acquired a new position in shares of Senseonics in the 3rd quarter worth approximately $117,000. Finally, Symmetry Partners LLC acquired a new stake in Senseonics during the 3rd quarter worth approximately $164,000. 12.36% of the stock is owned by hedge funds and other institutional investors.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.